{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:17:16Z","timestamp":1792451836948,"version":"4.5.0"},"reference-count":121,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Career Development Award from the Bladder Cancer Advocacy Network"},{"name":"Wilmot Physician-Scientist Fellowship Award"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction of immune checkpoint inhibitors and targeted agents has markedly improved outcomes and extended survival in urothelial and renal cell carcinoma. However, the substantial subset of cases are treatment-resistant. Emerging strategies aim to enhance the effectiveness of immunotherapy. One area of growing interest and promise is the microbiome. The microbiome plays a complex and dynamic role in regulating the immune system, and represents a new frontier as a promising target for modulating response to immunotherapy. This review summarizes recent advances in our understanding of the microbiome, its interactions with immunotherapy, novel avenues for microbiome modification, and potential implications for the treatment of urothelial and renal cell carcinoma.<\/jats:p>","DOI":"10.3390\/cancers17223606","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:47:27Z","timestamp":1762775247000},"page":"3606","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Microbiome and Genitourinary Cancers: A New Frontier"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0605-1971","authenticated-orcid":false,"given":"Timothy B.","family":"Winslow","sequence":"first","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Gupta","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedha Sai","family":"Vaddaraju","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6296-2473","authenticated-orcid":false,"given":"Brendan J.","family":"Guercio","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak M.","family":"Sahasrabudhe","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"ref_1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.11280","article-title":"Progress in the chemotherapy of metastatic cancer of the urinary tract","volume":"97","author":"Raghavan","year":"2003","journal-title":"Cancer"},{"key":"ref_3","first-page":"1541","article-title":"Chemotherapy for renal cell carcinoma","volume":"19","author":"Hartmann","year":"1999","journal-title":"Anticancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine\u2013Cisplatin in Advanced Urothelial Carcinoma","volume":"389","author":"Sonpavde","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1097\/JS9.0000000000001479","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: A global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S1139","DOI":"10.1016\/j.annonc.2024.08.2053","article-title":"1968P Study EV-103 dose escalation\/cohort A (DE\/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"35","author":"Rosenberg","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2025.43.5_suppl.439","article-title":"Nivolumab plus cabozantinib (N+C) vs. sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial","volume":"43","author":"Motzer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study","volume":"42","author":"Motzer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rysz, J., \u0141awi\u0144ski, J., Franczyk, B., and Gluba-Sagr, A. (2025). Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC). Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125577"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1038\/s41388-021-02019-6","article-title":"CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer","volume":"40","author":"Chen","year":"2021","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","article-title":"Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients","volume":"78","author":"Derosa","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.chom.2013.07.007","article-title":"Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment","volume":"14","author":"Kostic","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41423-020-00625-0","article-title":"Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids","volume":"18","author":"Kim","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mi.2014.44","article-title":"Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR\u2013S6K pathway","volume":"8","author":"Park","year":"2014","journal-title":"Mucosal Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/ibd\/izz046","article-title":"Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells\u2019 Differentiation and Function in Induction of Colitis","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_26","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_27","first-page":"1","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Alouini, S. (2024). Risk Factors Associated with Urothelial Bladder Cancer. Int. J. Environ. Res. Public Health, 21.","DOI":"10.3390\/ijerph21070954"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of Renal Cell Carcinoma: 2022 Update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2025.43.16_suppl.4505","article-title":"Nivolumab plus ipilimumab vs. sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial","volume":"43","author":"Choueiri","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamaoncol.2021.4337","article-title":"Treatment Selection in First-line Metastatic Renal Cell Carcinoma\u2014The Contemporary Treatment Paradigm in the Age of Combination Therapy","volume":"8","author":"Navani","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/JCO.2024.42.4_suppl.2","article-title":"First-line pembrolizumab plus lenvatinib for non\u2013clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study","volume":"42","author":"Voss","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1200\/JCO.2025.43.16_suppl.4514","article-title":"Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC)","volume":"43","author":"Haas","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2025.43.16_suppl.4500","article-title":"Nivolumab plus ipilimumab (NIVO+IPI) vs. gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial","volume":"43","author":"Galsky","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.2025.43.5_suppl.664","article-title":"EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs. chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"43","author":"Powles","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Balar, A.V., Kamat, A.M., Kulkarni, G.S., Uchio, E.M., Boormans, J.L., Roumigui\u00e9, M., Krieger, L.E.M., Singer, E.A., Bajorin, D.F., and Grivas, P. (2021). Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unre-sponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study. Lancet Oncol.","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"ref_43","unstructured":"(2025, September 25). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, Version 1.2026. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf."},{"key":"ref_44","unstructured":"(2025, September 25). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 1.2025. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Sati, N., Boyne, D.J., Cheung, W.Y., Cash, S.B., and Arora, P. (2021). Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw. Open, 4.","DOI":"10.1001\/jamanetworkopen.2020.34201"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00394-025-03743-5","article-title":"The association between diet and bladder cancer risk: A two-sample mendelian randomization","volume":"64","author":"Dai","year":"2025","journal-title":"Eur. J. Nutr."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Tini, S., Baima, J., Pigni, S., Antoniotti, V., Caputo, M., De Palma, E., Cerbone, L., Grosso, F., La Vecchia, M., and Bona, E. (2025). The Microbiota\u2013Diet\u2013Immunity Axis in Cancer Care: From Prevention to Treatment Modulation and Survivorship. Nutrients, 17.","DOI":"10.3390\/nu17172898"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Yang, B.-Y., Zhao, F.-Z., Li, X.-H., Zhao, M.-S., Lv, J.-C., Shi, M.-J., Li, J., Zhou, Z.-Y., Wang, J.-J., and Song, J. (2023). Alteration of pro-carcinogenic gut microbiota is associated with clear cell renal cell carcinoma tumorigenesis. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1133782"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1186\/s12885-023-11383-3","article-title":"Causal associations between gut microbiota and urological tumors: A two-sample mendelian randomization study","volume":"23","author":"Mingdong","year":"2023","journal-title":"BMC Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Yang, H.J., Kim, D.S., Lee, K.W., and Kim, Y.H. (2022). The Urinary Microbiome; Axis Crosstalk and Short-Chain Fatty Acid. Diagnostics, 12.","DOI":"10.3390\/diagnostics12123119"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Giery\u0144ska, M., Szulc-D\u0105browska, L., Struzik, J., Mielcarska, M.B., and Gregorczyk-Zboroch, K.P. (2022). Integrity of the Intestinal Barrier: The Involvement of Epithelial Cells and Microbiota\u2014A Mutual Relationship. Animals, 12.","DOI":"10.3390\/ani12020145"},{"key":"ref_52","unstructured":"Panneerselvam, D., and Vaqar, S. (2025). Peyer Patches, StatPearls Publishing."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: Function, regulation and therapeutic potential","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.autrev.2012.10.012","article-title":"Role of secretory IgA in infection and maintenance of homeostasis","volume":"12","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1126\/science.aar6918","article-title":"The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies","volume":"359","author":"Zitvogel","year":"2018","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nri.2017.7","article-title":"Dysbiosis and the immune system","volume":"17","author":"Levy","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4049\/jimmunol.1701019","article-title":"Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment","volume":"200","author":"Fenselau","year":"2018","journal-title":"J. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-20-0304","article-title":"Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma","volume":"11","author":"Zhang","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Gaskarth, D.A., Fan, S., Highton, A.J., and Kemp, R.A. (2025). The microbial metabolite butyrate enhances the effector and memory functions of murine CD8+ T cells and improves anti-tumor activity. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1577906"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"14430","DOI":"10.1038\/s41598-018-32860-x","article-title":"Regulation of the effector function of CD8+ T cells by gut microbiota-derived metabolite butyrate","volume":"8","author":"Luu","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature12721","article-title":"Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells","volume":"504","author":"Furusawa","year":"2013","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Liu, J., Tian, R., Sun, C., Guo, Y., Dong, L., Li, Y., and Song, X. (2023). Microbial metabolites are involved in tumorigenesis and development by regulating immune responses. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1290414"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Tong, Y., and Lou, X. (2025). Interplay between bile acids, gut microbiota, and the tumor immune microenvironment: Mechanistic insights and therapeutic strategies. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1638352"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1126\/science.adl4100","article-title":"Bile acid synthesis impedes tumor-specific T cell responses during liver cancer","volume":"387","author":"Varanasi","year":"2025","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e09533","DOI":"10.1002\/advs.202409533","article-title":"Tryptophan Metabolite Indole-3-Aldehyde Induces AhR and c-MYC Degradation to Promote Tumor Immunogenicity","volume":"12","author":"Cui","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e70703","DOI":"10.1002\/cam4.70703","article-title":"The Kynurenine Pathway and Indole Pathway in Tryptophan Metabolism Influence Tumor Progression","volume":"14","author":"Lu","year":"2025","journal-title":"Cancer Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41564-024-01737-3","article-title":"Dietary fibre directs microbial tryptophan metabolism via metabolic interactions in the gut microbiota","volume":"9","author":"Sinha","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"218016","DOI":"10.1016\/j.canlet.2025.218016","article-title":"Polyamines in pancreatic cancer: Reshaping the immunosuppressive tumor microenvironment","volume":"633","author":"Jiang","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1158\/0008-5472.CAN-23-2521","article-title":"PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma","volume":"84","author":"Shu","year":"2024","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1200\/JCO.2023.41.16_suppl.4564","article-title":"Microbial metabolism of tryptophan is associated with resistance to immune checkpoint (ICB) therapy in renal cell cancer (RCC)","volume":"41","author":"Bari","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Cookson","year":"2024","journal-title":"BMJ"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: The randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"De Santis, M., Redorta, J.P., Nishiyama, H., Krawczy\u0144ski, M., Seyitkuliev, A., Novikov, A., Guerrero-Ramos, F., Zukov, R., Kato, M., and Kawahara, T. (2025). Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): Final analysis of a randomised, open-label, phase 3 trial. Lancet.","DOI":"10.1016\/S0140-6736(25)01897-5"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Roupret, M., Bertaut, A., Pignot, G., Neuzillet, Y., Houede, N., Mathieu, R., Corbel, L., Besson, D., Seisen, T., and Jaffrelot, L. (2025). ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC). Ann. Oncol.","DOI":"10.1016\/j.annonc.2025.09.017"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.euo.2023.02.004","article-title":"Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon\u2013degrading Bacteria Among Bladder Cancer Patients","volume":"6","author":"Bukavina","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Elgormus, Y., Okuyan, O., Dumur, S., Sayili, U., and Uzun, H. (2023). Evaluation of new generation systemic immune-inflammation markers to predict urine culture growth in urinary tract infection in children. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1201368"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","article-title":"T-Cell Exhaustion: Characteristics, Causes and Conversion","volume":"129","author":"Yi","year":"2010","journal-title":"Immunology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"Pitt","year":"2015","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2022.0494","article-title":"The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm","volume":"8","author":"Liu","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Yin, Z., Liu, B., Feng, S., He, Y., Tang, C., Chen, P., Wang, X., and Wang, K. (2023). A Large Genetic Causal Analysis of the Gut Microbiota and Urological Cancers: A Bidirectional Mendelian Randomization Study. Nutrients, 15.","DOI":"10.3390\/nu15184086"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Bukavina, L., Calaway, A., Isali, I., Prunty, M., Sindhani, M., Ghannoum, M., Retuerto, M., MacLennan, G., Markt, S., and Ponsky, L. (2022). MP56-10 CHARACTERIZATION AND FUNCTIONAL ANALYSIS OF MICROBIOME IN BLADDER CANCER. J. Urol., 207.","DOI":"10.1097\/JU.0000000000002639.10"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2023.12.014","article-title":"Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer","volume":"85","author":"Pederzoli","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.1158\/1078-0432.CCR-15-0724","article-title":"Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor\u2013Tyrosine Kinase Inhibitors","volume":"21","author":"Pal","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/cas.15666","article-title":"Probiotics enhances anti-tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer","volume":"114","author":"Miyake","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","article-title":"Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome","volume":"187","author":"Derosa","year":"2024","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41467-022-28034-z","article-title":"Microbiome differential abundance methods produce different results across 38 datasets","volume":"13","author":"Nearing","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e202895","DOI":"10.1001\/jamanetworkopen.2020.2895","article-title":"Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors","volume":"3","author":"Nomura","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1182\/blood-2024-205005","article-title":"Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate","volume":"144","author":"Barea","year":"2024","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2249143","DOI":"10.1080\/19490976.2023.2249143","article-title":"Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell","volume":"15","author":"Zhu","year":"2023","journal-title":"Gut Microbes"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1038\/s41467-021-24331-1","article-title":"Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer","volume":"12","author":"Luu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2025.43.16_suppl.4508","article-title":"ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study","volume":"43","author":"Srour","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Grunewald, C.M., Haist, C., K\u00f6nig, C., Petzsch, P., Bister, A., N\u00f6\u00dfner, E., Wiek, C., Scheckenbach, K., K\u00f6hrer, K., and Niegisch, G. (2021). Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.782448"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Panebianco, C., Villani, A., Pisati, F., Orsenigo, F., Ulaszewska, M., Latiano, T.P., Potenza, A., Andolfo, A., Terracciano, F., and Tripodo, C. (2022). Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models. Biomed. Pharmacother., 151.","DOI":"10.1016\/j.biopha.2022.113163"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","article-title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: A new independent prognostic factor?","volume":"30","author":"Elkrief","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"eabo2296","DOI":"10.1126\/science.abo2296","article-title":"A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers","volume":"380","author":"Fidelle","year":"2023","journal-title":"Science"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Crespin, A., Le Bescop, C., de Gunzburg, J., Vitry, F., Zalcman, G., Cervesi, J., and Bandinelli, P.-A. (2023). A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1075593"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","article-title":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: A randomized phase 1 trial","volume":"28","author":"Dizman","year":"2022","journal-title":"Nat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1038\/s41591-024-03086-4","article-title":"Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: A randomized phase 1 trial","volume":"30","author":"Ebrahimi","year":"2024","journal-title":"Nat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"S1264","DOI":"10.1016\/j.annonc.2024.08.2320","article-title":"LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial","volume":"35","author":"Ciccarese","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2020","journal-title":"Science"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","article-title":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: A phase I trial","volume":"29","author":"Routy","year":"2023","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"S707","DOI":"10.1016\/j.annonc.2024.08.1126","article-title":"1068P Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)","volume":"35","author":"Elkrief","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.chom.2024.06.010","article-title":"Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor","volume":"32","author":"Kim","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"102315","DOI":"10.1016\/j.eclinm.2023.102315","article-title":"Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: An open-label, single-arm, phase II trial (RENMIN-215)","volume":"66","author":"Zhao","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_110","unstructured":"(2025, October 02). Swog: Protocol Tracking Reports. Available online: https:\/\/members.swog.org\/protocoldevelopmentreports\/Dashboard.asp?k=6Fgsf5fadagsj5hhhshsf55gffa."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/2159-8290.CD-24-0066","article-title":"Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity","volume":"14","author":"Glitza","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12967-017-1175-y","article-title":"Influence of diet on the gut microbiome and implications for human health","volume":"15","author":"Singh","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/19490976.2017.1290756","article-title":"Dietary fiber and prebiotics and the gastrointestinal microbiota","volume":"8","author":"Holscher","year":"2017","journal-title":"Gut Microbes"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1186\/s12967-025-06586-0","article-title":"Gut microbiome changes and cancer immunotherapy outcomes associated with dietary interventions: A systematic review of preclinical and clinical evidence","volume":"23","author":"Somodi","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1200\/JCO.2023.41.16_suppl.4598","article-title":"Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)","volume":"41","author":"Guercio","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/jamaoncol.2022.7753","article-title":"Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma","volume":"9","author":"Bolte","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1186\/s12885-024-13234-1","article-title":"Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy","volume":"24","author":"Farias","year":"2024","journal-title":"BMC Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1200\/JCO.2025.43.16_suppl.9511","article-title":"Clinical outcomes of the DIET study: A randomized controlled phase 2 trial of a high fiber diet intervention (HFDI) in patients with melanoma receiving immune checkpoint blockade (ICB)","volume":"43","author":"Qiu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/2159-8290.CD-21-0808","article-title":"A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti\u2013PD-1 Resistance through Effects on the Gut Microbiota","volume":"12","author":"Messaoudene","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.3390\/curroncol30090570","article-title":"Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic","volume":"30","author":"Pang","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ferrere, G., Alou, M.T., Liu, P., Goubet, A.-G., Fidelle, M., Kepp, O., Durand, S., Iebba, V., Fluckiger, A., and Daill\u00e8re, R. (2021). Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. J. Clin. Investig., 6.","DOI":"10.1172\/jci.insight.145207"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3606\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:55:18Z","timestamp":1762775718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":121,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17223606"],"URL":"https:\/\/doi.org\/10.3390\/cancers17223606","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]}}}